JPRN-UMIN000011473
Completed
Phase 2
Phase II study of erlotinib monotherapy for patients with untreated advanced non-small cell lung cancer, poor performance status and positive EGFR mutation status (OSAKA-LCSG1304) - OSAKA-LCSG1304
OSAKA-LCSG0 sites23 target enrollmentAugust 27, 2013
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- OSAKA-LCSG
- Enrollment
- 23
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Problematic infection that requires anti\-biotic, anti\-fungal agent or anti\-viral agent (2\) Current or previous history of pulmonary fibrosis, interstitial pneumonitis or drug\-induced pneumonia, revealed by chest CT or with clinical symptoms (3\) A history of severe hypersensitivity against erlotinib (4\) Difficulty in oral administration of erlotinib, functional / organic impairment or inflammatory bowel disease that disturbs absorption of erlotinib (5\) Another active advanced malignancy that requires any concurrent treatment with treatment for lung cancer (6\) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy (7\) Psychologically ineligible (8\) Decision of ineligibility by a physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II study of erlotinib monotherapy for patients with advanced stage of non-small cell lung cancer, undetectable epidermal growth factor receptor (EGFR) mutations by PNA LNA PCR clamp method, but positive immuno-staining with anti-EGFR mutation-specific antibodies.on-small cell lung cancerJPRN-UMIN000014299Dept. of Respiratory Medicine, Osaka Police Hospital7
Completed
Phase 2
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29
Completed
Phase 2
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54
Recruiting
Phase 2
A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer PatientsObjective of the study is to investigate efficacy and safety of Erlotinib for previously treated non-small cell lung cancer patients.JPRN-UMIN000004680Tottori University, Faculty of Medicine,Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine27
Completed
Phase 2
Phase II study of Erlotinib for previously treated advanced or recurrent non-small-cell lung cancer with EGFR wild type and KRAS wild typeadvanced or recurrent non-small-cell lung cancerJPRN-UMIN000008398Gunma Uninersity Hospital30